Neurobiological Technologies Report issue

For profit Phase 3
Founded: Emeryville CA United States (1987)
Status: Defunct (2009)

Organization Overview

First Clinical Trial
2004
NCT00088166
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2006

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (2)

ancrod (Viprinexun) (2 trials)

corticorelin ovine triflutate (acthrel) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Edema (Phase 3)

Brain Infarction (Phase 3)

Brain Ischemia (Phase 3)

Brain Neoplasms (Phase 3)

Cerebral Infarction (Phase 3)

Edema (Phase 3)

Infarction (Phase 3)

Ischemia (Phase 3)

Stroke (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 2